Nuevocor Doses First Patient in NVC-001 Heart Disease Trial

Singapore, Paris, and Philadelphia, U.S., October 8, 2026

NVC-001 Enters First-in-Human Clinical Evaluation

The SUNBEAM-LMNA study is a multicenter, open-label, single ascending dose Phase 1/2 clinical trial evaluating NVC-001 in adults with recurrently progressive LMNA-related dilated cardiomyopathy. The trial is designed to investigate the safety and tolerability of a one-time intravenous infusion of the investigational therapy at three dose levels. In addition to its primary safety and tolerability objectives, the study will assess several secondary measures, including cardiac structure and function, arrhythmia burden, and quality of life. These assessments are intended to help researchers understand the therapy’s potential effects on patients with this inherited cardiovascular disease. As an early-stage clinical trial, the study will first focus on establishing an appropriate safety profile and evaluating the treatment in humans. Nuevocor Chief Executive Officer Al Gianchetti described the first-patient dosing milestone as an important step toward evaluating a new therapeutic approach based on mechanobiology. The company aims to develop treatments that address disease-driving mechanisms rather than only managing the symptoms associated with cardiomyopathy. Dr. Evan Kransdorf, the study’s principal investigator and Assistant Professor of Cardiology at the Smidt Heart Institute at Cedars-Sinai Medical Center, also highlighted the collaborative effort behind the clinical milestone. The study represents the transition of NVC-001 from preclinical development into human clinical evaluation.

FDA Fast Track Designation Supports Development

The FDA has granted Fast Track designation to NVC-001 for LMNA DCM, a severe inherited heart disease with substantial unmet medical need. Fast Track is intended to facilitate the development and expedite the review of investigational therapies that target serious conditions and may address unmet medical needs. The designation can provide opportunities for more frequent communication with the FDA during development and eligibility for Rolling Review, under which completed sections of a Biologics License Application may be submitted and reviewed before the full application is complete. Fast Track designation does not mean that a treatment has been approved or that its safety and effectiveness have been established. Eligibility for Priority Review or Accelerated Approval depends on meeting the relevant regulatory requirements. According to Nuevocor, there are currently no approved disease-modifying therapies specifically for LMNA DCM. The condition is associated with mutations in the LMNA gene, which encodes lamin A and lamin C, proteins that contribute to the structural stability of the cell nucleus. Defects involving these proteins can affect heart muscle cells exposed to repeated mechanical forces during cardiac contraction, contributing to disease progression, conduction abnormalities, arrhythmias, and heart failure.

Gene Therapy Targets the Mechanobiology of LMNA DCM

NVC-001 is an investigational AAV9-based gene therapy designed to deliver a gene encoding a dominant-negative form of the SUN1 protein. The approach aims to reduce mechanical forces transmitted to the nuclei of heart muscle cells and restore nuclear integrity, addressing a biological defect associated with LMNA DCM. In preclinical studies, Nuevocor reported improvements in survival and cardiac function, alongside a favorable safety profile. These findings provide the scientific rationale for advancing NVC-001 into clinical testing, although results observed in preclinical models do not establish that the treatment will be safe or effective in humans. LMNA DCM is an inherited form of dilated cardiomyopathy that can progress rapidly and is associated with a high risk of serious arrhythmias and sudden cardiac death. Advanced disease may lead to end-stage heart failure, for which heart transplantation can be an option. The condition therefore represents an area of significant unmet medical need. Through the SUNBEAM-LMNA trial, Nuevocor aims to evaluate whether NVC-001 can be developed into a disease-modifying treatment for affected adults. The first-patient dosing milestone and FDA Fast Track designation represent important development steps, while further clinical data will be needed to determine the therapy’s safety, tolerability, and potential clinical benefit.

Source: Nuevocor press release